Home › Therapeutic areas › Oncology › Myelofibrosis
Myelofibrosis (5 companies)
Companies with an active program in Myelofibrosis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 1 | Phase 3 | $3.59B | 9 |
| GERN | Geron | Oncology | 1 | Approved | $638M | 3 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 1 | Phase 3 | $184M | 5 |
| PRLD | Prelude Therapeutics | HematologyOncology Rare | 1 | Phase 1 | $287M | 3 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 2 | Approved | $852M | 7 |
No companies match.